Novartis Wins U.S. FDA Approval for First MS Pill

Novartis AG won U.S. regulatory approval to sell its multiple sclerosis medicine Gilenya, beating Merck KGaA in a race to market the first pill to slow the crippling disease.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.